QNRX

3.2802.35%
DH

Dennis H. Langer

Independent Director

Dr. Dennis H. Langer, M.D., J.D., serves as Independent Director at Empirico Inc. Dr. Langer serves as Independent Director at Creyon Bio, Inc. He has leadership experience in the pharmaceutical industry, developing and/or commercializing more than 60 products during his career. He holds many leadership roles for various public and private biotechnology, specialty pharmaceutical and diagnostic companies. He serves as Independent Director of Javelin Oncology, Inc. since November 2020. He served as Independent Director at Brooklyn ImmunoTherapeutics, Inc. since May 01, 2021 until June 05, 2022. He serves as a Clinical Professor in Department of Psychiatry at Georgetown University School of Medicine in Washington, DC since September 2003. Dr. Langer is Consultant of Patricia Industries (formerly known as Investor Growth Capital). He is Director of Quoin Pharmaceuticals, Ltd since October 28, 2021. He has executive and entrepreneurial experience in the pharmaceutical and biotechnology industry. Dr. Langer served as an Associate Clinical Investigator at Eli Lilly and Company from 1983 to 1984. From 2005 to May 2010, he served as the Managing Partner of Phoenix IP Ventures. Dr. Langer served as a Senior Vice President of Project & Portfolio Management and Senior Vice President of Research and Development at GlaxoSmithKline Plc from December 2000 to January 2004 and served as Vice President of Research and Development since September 1994. He was with GlaxoSmithKline from September 1994 to January 2004. Dr. Langer co-founded Iroko Pharmaceuticals, LLC. He served as the President of North American Operations at Dr. Reddy's Laboratories Ltd. from January 20, 2004 to July 8, 2005. In addition, he led the alliance and joint venture management function at Dr. Reddy's Laboratories. He held a variety of management positions involving increasing responsibility in the areas of global product development strategy, healthcare services and business strategy at Dr. Reddy's Laboratories. Dr. Langer served as a Senior Vice President of Product Development Strategy and Senior Vice President of Research and Development, Healthcare Services of SmithKline Beecham Limited. He served as the President and Chief Executive Officer of Neose Technologies, Inc. from 1991 to 1994. Dr. Langer served as the Chief Resident in Psychiatry at Yale University School of Medicine and held clinical fellowships in Psychiatry at Harvard Medical School, George Washington University School of Medicine and the National Institutes of Health. He has a broad base of experience in innovative research and development, commercial operations and business development gained through senior management positions with major pharmaceutical companies such as Eli Lilly, Abbott Laboratories and G. D. Searle, LLC. Dr. Langer serves as the Chairman of Light Sciences Oncology, Inc. and has been its Director since May 11, 2011. He serves as the Chairman of Scientific Advisory Board at InforMedix Holdings, Inc. Dr. Langer is a Director of the WhiteHead Institute for Biomedical Research and several private companies. Dr. Langer served as Chairman and Chief Executive Officer of AdvanDx, Inc. from January 2013 to August 2014 and serves as its Director. Dr. Langer serves as a Director of various public and private biotechnology, specialty pharmaceutical and diagnostic companies. He has been a Director of Sancilio & Company, Inc. since July 2012 and Braeburn Pharmaceuticals, Inc. since January 2016. He had been an Independent Director of Myriad Genetics Inc. since May 2004 until June 30, 2022. Dr. Langer served as a Director of Alzheon, Inc. since March 11, 2016 until November 2018. He had been a Director of enGene Holdings Inc. (formerly known as enGene, Inc.), since December 2015. He has been a Member of Scientific Advisory Board of iCeutica Inc. since June 20, 2005. Dr. Langer has been a Non-Executive Independent Director at Pernix Therapeutics Holdings, Inc. since November 04, 2016. He serves as a Director of Biotechnology Innovation Organization and Alliance for Aging Research. Dr. Langer serves as a Member of Advisory Board at Patricia Industries (formerly known as Investor Growth Capital). He serves on the Boards of Visitors at Columbia College and Columbia University. Dr. Langer served as a Member of Healthcare Advisory Board at Safeguard Scientifics, Inc. and had served as a Member of its Life Sciences Advisory Board. He served as a Director of Myrexis, Inc. from February 19, 2009 to January 23, 2013. He served as Director at Sirna Therapeutics, Inc. since August 2005 and in Auxilium Pharmaceuticals, Inc. from July 2007 to June 2010. He served as Director at EUSA Pharma (USA), Inc., (alternate name Jazz Pharmaceuticals (EUSA Pharma USA) Inc.) from June 14, 2005 to May 8, 2008 and in Pharmacopeia, Inc. from May 07, 2007 to December 2008. He served as a Director of Delcath Systems, Inc. from December 11, 2014 to April 3, 2016. Dr. Langer served as a Director of Shire Human Genetic Therapies Inc. (also known as Transkaryotic Therapies, Inc.) since November 2003 and Iroko Pharmaceuticals, LLC. He served as a Director of Inotek Pharmaceuticals Corporation since February 14, 2007. Dr. Langer served as a Director of Ception Therapeutics, Inc. and Cytogen Corporation. He also served on the Board of Dicerna Pharmaceuticals, Inc. since November 2007 until September 18, 2019. He served as a Director of Innocoll GmbH (now Innocoll Holdings plc). Dr. Langer has published over 30 articles in peer reviewed medical journals. He holds J.D., cum laude, from Harvard Law School, an M.D. from Georgetown University School of Medicine and a B.A. in Biology from Columbia University. He had been Lead Independent Director of Sancilio Pharmaceuticals Company, Inc., since October 2014 and had been its Director since February 2012.

Positions